Senti closes $10M convertible debt deal, discloses potential $60M Celadon merger

Filed May 26, 2026 · Period ending May 20, 2026 · ~1 min read

Key Changes

• high

  Senti's subsidiary issued $10 million in senior secured convertible notes to Celadon Partners on May 20, 2026. These notes can convert to equity, potentially diluting existing shareholders, and have priority claim on company assets.

  Item 1.01 verify on EDGAR →
• high

  Company disclosed potential merger with Celadon affiliate that would give shareholders contingent value rights worth up to $60 million total, payable only if drug candidate SENTI-202 hits regulatory and sales milestones.

  Item 9.01 verify on EDGAR →
• high

  Proposed transactions require shareholder vote. Company will file proxy materials with SEC and hold special meeting for approval of additional convertible note issuances and potential Celadon merger.

  Item 9.01 verify on EDGAR →